A functionalized 20-residue peptaibol derivative for nucleic acid delivery

Area of Science:

• Biotechnology
• Molecular Biology
• Drug Delivery

Background:

• Antisense oligodeoxynucleotides (ASOs) hold therapeutic potential but require efficient delivery vehicles.
• Peptaibols, like trichocellin-A-I, are known for membrane interaction and modification.
• Developing targeted cellular delivery systems is crucial for ASO efficacy.

Purpose of the Study:

• To design and synthesize a novel peptide-based carrier for cellular delivery of antisense oligodeoxynucleotides.
• To investigate the cellular uptake mechanism and efficiency of the designed peptide-oligonucleotide complex in different cell lines.
• To evaluate the secondary structure and stability of the novel peptide carrier.

Main Methods:

• Solid-phase synthesis using Fmoc protocol and amino acid fluorides to create the transporter peptide.
• Circular dichroism spectroscopy to analyze the secondary structure of the peptide.
• Confocal laser-scanning microscopy to visualize and quantify the cellular uptake of the peptide-oligonucleotide complex in NIH3T3 and A549 cells.

Main Results:

• A novel transporter peptide (2) was synthesized, exhibiting a predominantly alpha-helical structure in solution.
• The peptide-oligonucleotide complex efficiently translocated into the cytoplasm of mouse embryonal fibroblast (NIH3T3) cells.
• In human lung carcinoma (A549) cells, the complex showed accumulation around the plasma membrane, indicating cell-type specific uptake.

Conclusions:

• The designed peptide transporter demonstrates potential for antisense oligodeoxynucleotide delivery, with cell-specific uptake characteristics.
• Further optimization may be needed to enhance cytoplasmic delivery in certain cell types, such as A549 cells.
• This study highlights the utility of modified peptaibols as carriers for nucleic acid-based therapeutics.